In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma Meeting Abstract


Authors: Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; Ganesan, N.; Lubin, L.; Kim, Y. H.; Khodadoust, M.; Almazan, T.; Dai, J.; Jacobsen, E. D.; Weinstock, D. M.; Horwitz, S. M.
Abstract Title: In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419402069
PROVIDER: wos
DOI: 10.1182/blood.V130.Suppl_1.819.819
Notes: Meeting Abstract: 819 -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Steven M Horwitz
    540 Horwitz
  2. Alison Moskowitz
    261 Moskowitz
  3. Patricia Myskowski
    205 Myskowski
  4. Ahmet Dogan
    331 Dogan
  5. Natasha   Galasso
    26 Galasso
  6. Theresa Davey
    13 Davey
  7. Monica Jignesh Shah
    1 Shah
  8. Nivetha Ganesan
    21 Ganesan
  9. Lakeisha C Lubin
    3 Lubin